
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
The American Journal of Managed Care
over 27 years ago
Economic Impact of Delaying or Preventing AIDS in Persons with HIVover 27 years ago
Erectile Dysfunction: The Primary Care Practitioner's Viewover 27 years ago
Drug-Nutrient Interactions





